GLYT1 transgenic mouse
    2.
    发明申请
    GLYT1 transgenic mouse 审中-公开
    GLYT1转基因小鼠

    公开(公告)号:US20050210540A1

    公开(公告)日:2005-09-22

    申请号:US11080962

    申请日:2005-03-15

    摘要: The present invention provides genetic constructs and methods for producing transgenic non-human animals comprising within their genome transgenic DNA encoding GLYT1. These transgenic animals could be further used to generate transgenic animals which produce more active GLYT1. Also provided are transgenic animals producing more GLYT1 protein, as well as the methods of producing same. The invention also relates to the use of these animals as a model for analyzing the effects of depressing synaptic NMDA receptor function and studying the ability of compounds to reduce symptoms of psychotic behavior.

    摘要翻译: 本发明提供用于产生转基因非人动物的遗传构建体和方法,其在其基因组中包含编码GLYT1的转基因DNA。 这些转基因动物可以进一步用于产生产生更活性的GLYT1的转基因动物。 还提供了产生更多GLYT1蛋白质的转基因动物以及其生产方法。 本发明还涉及这些动物作为分析抑制突触NMDA受体功能的作用并研究化合物降低精神病性症状的能力的模型。

    GLYT1 transgenic mouse
    3.
    发明申请
    GLYT1 transgenic mouse 审中-公开
    GLYT1转基因小鼠

    公开(公告)号:US20060070136A1

    公开(公告)日:2006-03-30

    申请号:US11274814

    申请日:2005-11-15

    IPC分类号: A01K67/027 C12N15/63

    摘要: The present invention provides genetic constructs and methods for producing transgenic non-human animals comprising within their genome transgenic DNA encoding GLYT1. These transgenic animals could be further used to generate transgenic animals which produce more active GLYT1. Also provided are transgenic animals producing more GLYT1 protein, as well as the methods of producing same. The invention also relates to the use of these animals as a model for analyzing the effects of depressing synaptic NMDA receptor function and studying the ability of compounds to reduce symptoms of psychotic behavior.

    摘要翻译: 本发明提供用于产生转基因非人动物的遗传构建体和方法,其在其基因组中包含编码GLYT1的转基因DNA。 这些转基因动物可以进一步用于产生产生更活性的GLYT1的转基因动物。 还提供了产生更多GLYT1蛋白质的转基因动物以及其生产方法。 本发明还涉及这些动物作为分析抑制突触NMDA受体功能的作用并研究化合物降低精神病性症状的能力的模型。

    Amino-piperidine derivatives
    5.
    发明授权
    Amino-piperidine derivatives 失效
    氨基哌啶衍生物

    公开(公告)号:US07176316B2

    公开(公告)日:2007-02-13

    申请号:US10778560

    申请日:2004-02-13

    IPC分类号: C07D211/56

    摘要: The present invention relates to compounds of the general formula wherein X and Y are each independently selected from —CH2— or —O—, with the proviso that X and Y are not simultaneously —O—; A is —S(O)2— or —C(O)—; and R1, R2, R3, and R4 are as defined in the specification. The compounds are GlyT-1 inhibitors and are useful for the treatment of psychoses, pain, dysfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

    摘要翻译: 本发明涉及通式的化合物,其中X和Y各自独立地选自-CH 2 - 或-O-,条件是X和Y不同时为-O-; A是-S(O)2 - 或-C(O) - ; R 1,R 2,R 3,R 4和R 4如说明书中所定义。 化合物是GlyT-1抑制剂,可用于治疗精神病,疼痛,记忆功能障碍,学习障碍,精神分裂症,痴呆等认知过程受损的其他疾病,如注意力缺陷障碍或阿尔茨海默病。